Number of the records: 1  

2,6,9-Trisubstituted purines as CRK3 kinase inhibitors with antileishmanial activity in vitro

  1. 1.
    SYSNO ASEP0446880
    Document TypeJ - Journal Article
    R&D Document TypeJournal Article
    Subsidiary JČlánek ve WOS
    Title2,6,9-Trisubstituted purines as CRK3 kinase inhibitors with antileishmanial activity in vitro
    Author(s) Řezníčková, Eva (UEB-Q) RID, ORCID
    Popa, Alexandr (UEB-Q)
    Gucký, Tomáš (UEB-Q) ORCID
    Zatloukal, Marek (UEB-Q) ORCID
    Havlíček, Libor (UEB-Q) RID, ORCID
    Bazgier, Václav (UEB-Q) ORCID, RID
    Berka, K. (CZ)
    Jorda, Radek (UEB-Q) ORCID, RID
    Popa, Igor (UEB-Q)
    Nasereddin, A. (IL)
    Jaffe, Ch. L. (IL)
    Kryštof, Vladimír (UEB-Q) RID, ORCID
    Strnad, Miroslav (UEB-Q) RID, ORCID
    Source TitleBioorganic and Medicinal Chemistry Letters. - : Elsevier - ISSN 0960-894X
    Roč. 25, č. 11 (2015), s. 2298-2301
    Number of pages4 s.
    Languageeng - English
    CountryGB - United Kingdom
    KeywordsPurine ; Cyclin-dependent kinase ; Leishmania
    Subject RIVEB - Genetics ; Molecular Biology
    R&D ProjectsLO1204 GA MŠMT - Ministry of Education, Youth and Sports (MEYS)
    Institutional supportUEB-Q - RVO:61389030
    UT WOS000354115400007
    DOI10.1016/j.bmcl.2015.04.030
    AnnotationHere we describe the leishmanicidal activities of a library of 2,6,9-trisubstituted purines that were screened for interaction with Cdc2-related protein kinase 3 (CRK3) and subsequently for activity against parasitic Leishmania species. The most active compound inhibited recombinant CRK3 with an IC50 value of 162 nM and was active against Leishmania major and Leishmania donovani at low micromolar concentrations in vitro. Its mode of binding to CRK3 was investigated by molecular docking using a homology model.
    WorkplaceInstitute of Experimental Botany
    ContactDavid Klier, knihovna@ueb.cas.cz, Tel.: 220 390 469
    Year of Publishing2016
Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.